Has Jien Shim, MD received payments from drug or device companies?

Yes. Drug and device makers reported $656 in general payments to Jien Shim, MD across 12 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jien Shim, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jien Shim, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jien Shim, MD

Endocrinology, Diabetes & Metabolism · Menlo Park, CANPI 1275875957

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 12 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by BETA Bionics, Inc. at 37.6% of the total. Reporting peaked in 2023 at $396 and has fallen 58.3% since, to $165 in 2025. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in CA, where the typical reported total is $1,096.

$656in general payments, 2019–2025

Across 12 payments — averaging $54.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

BETA Bionics, Inc.$247
Amgen$132
Insulet Corporation$95
Acella Pharmaceuticals, LLC$67
Medtronic$57
Abbott$38
plus $21 from 1 others

What the payments were for

Food & beverage$656100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
BETA Bionics, Inc.	2	$247
Amgen(2 entities)	2	$132
Insulet Corporation	2	$95
Acella Pharmaceuticals, LLC	1	$67
Medtronic	2	$57
Abbott	2	$38
Sequel Med Tech, LLC	1	$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

iLet Bionic Pancreas$651
TEPEZZA$112

How this compares

$656 in reported general payments places this provider in the 40th percentile of 952 endocrinology, diabetes & metabolism providers in California.

See all endocrinology, diabetes & metabolism providers in California →

Medicare billing

Part B allowed, 2024

$365,054

Medicare patients

867

Services billed

9,952

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
MounjaroTirzepatide	124	$161,971
OzempicSemaglutide	107	$146,883
JardianceEmpagliflozin	58	$77,447
TrulicityDulaglutide	45	$70,667
RybelsusSemaglutide	29	$49,656
FarxigaDapagliflozin Propanediol	27	$43,528
TymlosAbaloparatide	13	$42,225
JanuviaSitagliptin Phosphate	19	$28,154
Tresiba Flextouch U-100Insulin Degludec	44	$24,148
Cinacalcet Hcl	14	$15,192
Tresiba Flextouch U-200Insulin Degludec	13	$10,607
LyumjevInsulin Lispro-Aabc	13	$9,624
Cequr SimplicityBolus Insulin Pump, 200 Unit	15	$8,146
Humalog Kwikpen U-100Insulin Lispro	33	$7,341
TradjentaLinagliptin	11	$6,868

Paid to pharmacies, not to this prescriber.

Other endocrinology, diabetes & metabolism in Menlo Park

Juan FriasSan Diego$1.4M
Joselito CabaccanSan Jose$1.4M
Daniel NadeauNewport Beach$1.2M
Yehuda HandelsmanTarzana$1M
Helen BaronRancho Mirage$958K
Ken FujiokaSan Diego$747K
Minou TranPico Rivera$663K
James ChuMonterey$639K
Anthony HeaneyLos Angeles$588K
Daniel Einhornla Jolla$578K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →